A Phase II Multicenter, Two Stage Design Open Label Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2014
At a glance
- Drugs Eribulin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 31 Aug 2018 Biomarkers information updated
- 14 May 2012 Actual patient number is 108 according to ClinicalTrials.gov.
- 21 Apr 2012 Additional locations (Hungary, Spain, United Kingdom) added as reported by European Clinical Trials Database record.